Ondine Receives a Health Canada License for the use of Periowave(TM) to treat Gingivitis



    VANCOUVER, March 19 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) today announced that it has received a Health Canada license for use
of the Periowave(TM) Photodisinfection system for the treatment of gingivitis.
Gingivitis is an inflammation of the gums that affects up to 80% of the
population, and can lead to serious forms of gum disease including
periodontitis.
    "Periowave(TM) destroys bacteria that can attach to tooth and root
surfaces, resulting in an effective and painless new approach to the treatment
of gingivitis," said Carolyn Cross, CEO and president of Ondine Biopharma.
"This additional indication represents an opportunity for clinicians to treat
gum disease at an early stage. Nine out of ten Canadians will experience an
episode of gingivitis at least once in their lives. Early treatment can
inhibit progression of gum disease and the resulting systemic effects such as
diabetes, stroke, and heart disease."

    About Gingivitis:
    Gingivitis is one of the most common forms of gum disease. Gingivitis is
an inflammatory condition that often results in swollen, red, or bleeding
gums. Scientists believe that plaque-forming bacteria living in the mouth and
on tooth surfaces are the primary cause of gingivitis. Reduction of plaque
bacteria can decrease inflammation and thereby cause a reduction in the
gingivitis index. Left untreated, gingivitis can evolve into periodontitis, a
condition which can result in loss of teeth and the supporting bone, and is
closely correlated to the development of serious systemic disorders.

    About Periowave(TM) and Photodisinfection (PDD):
    Periowave(TM) is a Photodisinfection system developed by Ondine that
utilizes low-intensity lasers and wavelength-specific, light-activated
compounds to specifically target and destroy microbial pathogens and reduce
the symptoms of disease. The compounds are generally topically applied and one
or more lasers are used to activate the compounds and complete the
disinfection. The Photodisinfection technologies were developed by Professor
Michael Wilson and colleagues at the Eastman Dental Institute, University
College London, and licensed to Ondine by UCL Biomedica PLC, University
College London. Additional information about Periowave(TM) is available at
www.periowave.com.

    About Ondine Biopharma Corporation:
    Ondine is developing non-antibiotic therapies for the treatment of a
broad spectrum of bacterial, fungal and viral infections. The Company is
focused on creating and commercializing leading-edge products utilizing its
patented light-activated technology. Photodisinfection provides broad-spectrum
antimicrobial efficacy without encouraging the formation and spread of
antibiotic resistance.
    The Company is headquartered in Vancouver, British Columbia, Canada, with
a research laboratory in Redmond, Washington, USA, a sales and marketing
subsidiary in York, Pennsylvania, and an international office in St Michael,
Barbados. For additional information, please visit the Company's website at:
www.ondinebiopharma.com.

    Forward-Looking Statements:
    Certain statements contained in this release containing words like
"believe", "intend", "may", "expect" and other similar expressions, are
forward-looking statements that involve a number of risks and uncertainties.
Factors that could cause actual results to differ materially from those
projected in the Company's forward-looking statements include the following:
market acceptance of our technologies and products; our ability to obtain
financing; our financial and technical resources relative to those of our
competitors; our ability to keep up with rapid technological change;
government regulation of our technologies; our ability to enforce our
intellectual property rights and protect our proprietary technologies; the
ability to obtain and develop partnership opportunities; the timing of
commercial product launches; the ability to achieve key technical milestones
in key products and other risk factors identified from time to time in the
Company's filings.





For further information:

For further information: Carolyn Cross, President and Chief Executive
Officer, Ondine Biopharma Corporation, (604) 669-0555,
ccross@ondinebiopharma.com; Christina Bessant, Investor Relations, The Equicom
Group Inc., (416) 815-0700 ext. 269, cbessant@equicomgroup.com

Organization Profile

ONDINE BIOPHARMA CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890